Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1993 1
1996 1
1997 1
1998 1
2001 1
2004 1
2006 1
2007 1
2008 1
2010 2
2011 1
2013 2
2014 2
2016 2
2017 3
2020 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Nogova L, et al. Among authors: ringeisen f. J Clin Oncol. 2017 Jan 10;35(2):157-165. doi: 10.1200/JCO.2016.67.2048. Epub 2016 Nov 21. J Clin Oncol. 2017. PMID: 27870574 Free PMC article. Clinical Trial.
[Breast carcinoma with predominant neuroendocrine differentiation].
Frachon S, Pasquier D, Treilleux I, Seigneurin D, Ringeisen F, Rosier P, Bolla M, Boutonnat J. Frachon S, et al. Among authors: ringeisen f. Ann Pathol. 2004 Jun;24(3):278-83. doi: 10.1016/s0242-6498(04)93966-1. Ann Pathol. 2004. PMID: 15480266 Review. French.
Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
Davie A, Cuyun Carter G, Rider A, Bailey A, Lewis K, Price G, Ostojic H, Ringeisen F, Pivot X. Davie A, et al. Among authors: ringeisen f. ESMO Open. 2021 Aug;6(4):100226. doi: 10.1016/j.esmoop.2021.100226. Epub 2021 Aug 7. ESMO Open. 2021. PMID: 34371379 Free PMC article.
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich RT, Reinhardt HC, Ringeisen F, Büttner R, Heukamp LC, Wolf J, Thomas RK. Malchers F, et al. Among authors: ringeisen f. Cancer Discov. 2014 Feb;4(2):246-57. doi: 10.1158/2159-8290.CD-13-0323. Epub 2013 Dec 3. Cancer Discov. 2014. PMID: 24302556 Free article.
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Beck JT, et al. Among authors: ringeisen f. Breast Cancer Res Treat. 2014 Feb;143(3):459-67. doi: 10.1007/s10549-013-2814-5. Epub 2013 Dec 21. Breast Cancer Res Treat. 2014. PMID: 24362951 Free PMC article. Clinical Trial.
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.
Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, Chandarlapaty S. Moynahan ME, et al. Among authors: ringeisen f. Br J Cancer. 2017 Mar 14;116(6):726-730. doi: 10.1038/bjc.2017.25. Epub 2017 Feb 9. Br J Cancer. 2017. PMID: 28183140 Free PMC article. Clinical Trial.
23 results